The results of the validation analysis revealed significant differences in the expression levels of the CCR7, CD19, CXCL13, CXCR4, and SELL genes between the disease groups (RA and UC) and the normal control group. This evidence concerns the gene CXCL13 and rheumatoid arthritis.